| Literature DB >> 34912464 |
Won Joo Suh1, Yuna Seo1, Chul Jin1, Seung-Yeon Cho1, Seong-Uk Park1, Woo-Sang Jung1, Sang-Kwan Moon1, Jung-Mi Park1, Chang-Nam Ko1, Seungwon Kwon1, Ki-Ho Cho1.
Abstract
This study aimed to analyze and summarize the existing evidence regarding herbal medicine treatments for amyotrophic lateral sclerosis (ALS). Studies on herbal medicine treatment in patients with ALS were searched within English, Chinese, Japanese, and Korean databases up to July 31, 2021. In the selected studies, we collected the following information: the first author, year of publication, country, language, study methodology, sample size, demographic characteristics of the study participants, disease duration, diagnostic criteria, treatment method, treatment periods, evaluation tools, results, and side effects. The organized data were classified and analyzed narratively. This study included 59 studies. The first clinical study on the effect of herbal medicine was published in 1995; moreover, most studies were conducted in China. Among the 59 selected studies, 47.5% were observational studies, including case reports and case series. Moreover, there was one meta-analysis. The El Escorial criteria were the most commonly used diagnostic criterion for ALS; moreover, the ALS functional rating scale was the most common evaluation tool. Buzhongyiqitang, Sijunzitangjiawei, and Jianpiyifeitang were the most commonly used herbal medicines, with anti-inflammatory, protein aggregation, and anti-oxidant effects. There remain evidence of gaps in the effectiveness of herbal medicine for ALS. To allow effective treatment of patients with ALS using herbal medicine, large-scale and rigorously designed high-quality clinical studies should be performed.Entities:
Year: 2021 PMID: 34912464 PMCID: PMC8668313 DOI: 10.1155/2021/5674142
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1PRISMA flow chart of the study selection process.
Figure 2Distribution of literature status according to year. Bubble size: the number of corresponding literature. RCT: randomized controlled trial.
General characteristics of the included literature (N = 59).
| Variables | Categories |
|
|---|---|---|
| Publication year | 1995–1999 | 4 (6.8) |
| 2000–2004 | 7 (11.9) | |
| 2005–2009 | 6 (10.2) | |
| 2010–2014 | 19 (32.2) | |
| 2015–2019 | 23 (40.0) | |
| Research methodology | Observational studies | 28 (47.5) |
| Case report | 19 (32.2) | |
| Case series | 6 (10.2) | |
| Retrospective study | 2 (3.4) | |
| Prospective study | 1 (1.7) | |
| Experimental studies | 20 (33.9) | |
| Before-and-after study | 12 (20.3) | |
| Randomized controlled trial | 8 (13.6) | |
| Literature studies | 11 (18.6) | |
| Narrative review | 7 (11.9) | |
| Systemic review | 3 (5.1) | |
| Meta-analysis | 1 (1.7) | |
| Country | China | 39 (66.1) |
| Korea | 20 (33.9) | |
| Language | Chinese | 34 (57.6) |
| Korean | 14 (23.7) | |
| English | 11 (18.6) |
Review of case reports.
| First author (year) | Country | Sex | Age | Duration of disease | Diagnosed by | Herbal medicine | Treatment duration | Other intervention | Outcomes | Significant finding |
|---|---|---|---|---|---|---|---|---|---|---|
| Wu (1995) [ | China | M | 37 | 2 y | EMG | Maqianzi powder | No mention | No mention | Clinical symptoms | Improving muscle strength |
| Kim et al. (2000) [ | Korea | F | 40 | 8 m | EMG | Shiquandabutang | 8 m | Riluzole | Clinical symptoms | Reducing dependence on a ventilator |
| Park et al. (2001) [ | Korea | F | 60 | 6 m | EMG | Shaoyaogancaotangjiawei | 2 m | Acupuncture | Clinical symptoms | Improving dysphagia, lalopathy, and hypotonia |
| Kim et al. (2004) [ | Korea | F | 50 | 8 m | EMG | Jiaweixiaoyaosan | 1 m | Riluzole | Clinical symptoms | Improving facial flushing and sweating |
| Yeon et al. (2010) [ | Korea | M | 32 | 2 y | EMG | Combination of several herbal medicines | 1 m | Acupuncture | Clinical symptoms | Improving low back pain, K-ODI scores, and K-ALSFRS-R scores |
| Wang et al. (2010) [ | China | M | 54 | 2 y | EMG | Buzhongyiqitangjiajian | 8 m | Huangqi injection | Clinical symptoms | Improving dysphagia, muscle strength, and appetite |
| Liang et al. (2012) [ | China | F | 48 | 3 y | EMG | Huangqiguizhiwuwutang | 3 m | Acupuncture | Clinical symptoms | Improving gait, dizziness, and muscle strength |
| Jeong et al. (2013) [ | Korea | M | 61 | 2 y | EMG | Wugongtang | 3 m | Trihexyphenidyl (stopped) | Clinical symptoms | Decreasing salivation |
| Jeong et al. (2013) [ | Korea | M | 53 | 2 y 3 m | EMG | Dihuangyinzi | 9m | Acupuncture | Body weight | Increasing body weight, BMI, and SNAQ score |
| Lee et al. (2014) [ | Korea | M | 56 | 2 y | EMG | Chungpajeongami | 3 y | Acupuncture | SpO2 | Maintaining SpO2, EtCO2, and Vte |
| Jo et al. (2014) [ | Korea | M | 49 | 20 m | No mention | Shiquandabutang | 5 m | Acupuncture | Clinical symptoms | Maintaining respiratory function and speech |
| Sun and Xu (2014) [ | China | M | 42 | 2 y | EMG | Buzhongyiqitangjiajian | 2 m | Electroacupuncture | Clinical symptoms | Reducing fatigue, stomach discomfort, and constipation |
| Zhong et al. (2014) [ | China | M | 57 | 1 y | EMG | Combination of several herbal medicines | 1 y | No mention | Clinical symptoms | Improving muscle strength |
| Lu and Zhao (2015) [ | China | F | No mention | 1 y | EMG | Bushenkangshuaipian | 3 w | No mention | Clinical symptoms | Improving mental state, appetite, and muscle strength |
| Kim et al. (2016) [ | Korea | F | 52 | 6 y | EMG | Jianghuodihuangtangjiajian | 11 d | Acupuncture | GAS | Improving the GAS of the weakness of the upper and lower extremities |
| Cha et al. (2016) [ | Korea | M | 43 | 3 y | EMG | Glycyrrhiza uralensis extract | 3 m | Acupuncture | CK level | Decreasing CK levels |
| Qiu et al. (2016) [ | China | F | 41 | 3 y | El Escorial criteria | Dihuangyinzi | 12 y | Riluzole (stopped after 1 month) | Clinical symptoms | Not requiring permanent continuous ventilator |
| Cao et al. (2017) [ | China | M | 47 | 2 y | No mention | Liuweidihuangwan + Buzhongyiqitangjiajian | 6 w | No mention | Clinical symptoms | Reducing sweating, hot flash, muscle fibrillation, improving muscle strength, appetite, and sleep |
| Liu et al. (2018) [ | China | M | 64 | 2 y | EMG | Liuweidihuangtang + Bazhentangjiajian | 2 m | Acupuncture | Clinical symptoms | Improving weakness of the upper limbs and tongue stiffness |
Details are not specified. Astragali Radix, Codonopsis Pilosulae Radix, Achyranthis Radix, Eucommiae Cortex, Homalomenae Rhizoma, Cnidii Rhizoma, Psoraleae Semen, Salviae Miltiorrhizae Radix, Leonuri Herba, Glycyrrhizae Radix et Rhizoma, and Ostreae Testa. M, male; F, female; d, day(s); w, week(s); m, month(s); y, year(s); EMG, electromyography; MRI, magnetic resonance imaging; NCS, nerve conduction study; ALSFRS, amyotrophic lateral sclerosis functional rating scale; ALSFRS-R, ALSFRS-Revised; K-ALSFRS-R, Korean-ALSFRS-R; K-ODI, Korean Oswestry Disability Index; MRC, Medical Research Council; SNAQ, Simplified Nutritional Appetite Questionnaire; GAS, global assessment scale; BMI, body mass index; CK, creatine kinase; SpO2, saturation by pulse oximetry; EtCo2, =end-tidal CO2 concentration; and Vte, exhaled tidal volume.
Review of the case series.
| First author (year) | Country | Sample size | Sex (M: F) | Average age | Duration of disease | Diagnosed by | Herbal medicine | Duration of treatment | Other intervention | Outcomes | Significant finding |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Liang (1999) [ | China | 24 | 17:7 | 43 | 5 y | EMG | Maqianzi powder | No mention | Acupuncture | TER | TER 91.67% |
| Cheng Y (1999) [ | China | 46 | 27:19 | No mention | No mention | EMG | Sanqifuweiruansuowan | 6–24 m | Acupuncture | TER | TER 89.13% |
| Luo et al. (2002) [ | China | 26 | 15:11 | 47.9 | No mention | 3,200 diagnostic criteria for medical diseases | Qiangjiling | 3 m | Huangqi injection | TER | TER 68.75% |
| Kwon (2003) [ | Korea | 18 | No mention | No mention | No mention | EMG biopsy | Yangzuezhuangjinjianbuwan | 3–6 m | Acupuncture | Clinical symptoms | Inhibition of progression |
| Byun et al. (2007) [ | Korea | 3 | 0:3 | 53.3 | 1.67 y | No mention | Liujunzitang | 1.5–6 m | Acupuncture riluzole | ALSFRS | Delayed symptoms |
| Ryu et al. (2009) [ | Korea | 2 | 1:1 | 50 | 4.75 y | No mention | Bawutang | 1–2 m | Acupuncture | K-ALSFRS-R | Improving local symptoms |
Astragali Radix, Codonopsis Pilosulae Radix, Atractylodis Rhizoma Alba, Citri Unshius Pericarpium, Gastrodiae Rhizoma, Bupleuri Radix, Rehmanniae Radix Preparata, Rehmanniae Radix Recens, Dipsaci Radix, Cuscutae Semen, Lycii Fructus, Epimedii Herba, Phellodendri Cortex, Anemarrhenae Rhizoma, Paeoniae Radix, and Glycyrrhizae Radix et Rhizoma. M, male; F, female; m, month(s); y, year(s); TER, total effective rate; ALSFRS, amyotrophic lateral sclerosis functional rating scale; K-ALSFRS-R, Korean-ALSFRS-Revised; and ALSSS, Amyotrophic lateral sclerosis severity scale.
Review of retrospective studies.
| First author (year) | Country | Sample size | Sex (M:F) | Average age | Duration of disease (average) | Diagnosed by | Outcomes |
|---|---|---|---|---|---|---|---|
| Jeon et al. (1997) [ | Korea | 17 | 12:5 | 52.4 | No mention | Diagnostic criteria by Jokelainen et al. | Analyzing the age of onset, clinical signs, ALS type, treatment methods, outcomes, etc. |
| Li et al. (2017) [ | China | 288 | 169:119 | No mention | No mention | El Escorial criteria | Analyzing the clinical characteristics, survival rate, and TCM syndrome in patients with ALS |
M, male; F, female; ALS, amyotrophic lateral sclerosis; and TCM, traditional Chinese medicine.
Review of prospective Study.
| First author (year) | Country | Sample size | Sex (M:F) | Average age | Duration of disease (average) | Diagnosed by | Outcomes |
|---|---|---|---|---|---|---|---|
| Pan et al. (2013) [ | China | 231 | 148:83 | 63.2 | 2.1 y | El Escorial criteria | Analyzing the basic patient characteristics, IT usage status, reasons for using IT, Chinese medicine usage status, IT efficacy, and IT cost |
M, male; F, female; y, year(s); and IT, integrative therapy.
Review of before-and-after studies.
| First author (year) | Country | Sample size | Sex (M:F) | Average age | Duration of disease (average) | Diagnosed by | Herbal medicine | Duration of treatment | Other intervention | Outcomes | Significant findings | Side effects |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liu (2001) [ | China | 32 | 24:8 | 51.5 | No mention | The latest domestic and foreign disease diagnosis guidelines | Jianpibushen decoction | 9 m | None | TER | TER 84.38% | None |
| Liu et al. (2006) [ | China | 40 | 31:9 | No mention | 3–36 m (19.2 m) | Chinese Medical Association Neurology Branch | Jianpibushenxifeng decoction | 3 m | Huangqi injection | Clinical symptoms | Improvement in speaking, eating, bed arrangement, running, and climbing stairs | No mention |
| Kim et al. (2009) [ | Korea | 12 | 6:6 | 50 | (43.41 m) | El Escorial criteria | Combination of several herbal medicines | 30 d | Acupuncture | ALSFRS-R | An increase in the scores of the ALSFRS-R and MRC muscle scale | No mention |
| Kim et al. (2010) [ | 3 m | Acupuncture | ALSFRS-R | Slower progression compared with patients without Oriental medical treatment | No mention | |||||||
| Sun (2009) [ | China | 23 | 18:5 | No mention | 3–84 m (18 m) | El Escorial criteria | Jianpiyifei decoction | 3 m | None | ALSFRS | Enhancement of motor functions(feeding, clothing, writing, and bed emancipated) | None |
| Zhong (2011) [ | China | 20 | 14:6 | No mention | 2–72 m (17.2 m) | El Escorial criteria | Jianpiyifei decoction | 5 m | None | ALSFRS-R | Delayed disease progression | None |
| Li (2012) [ | China | 28 | 17:11 | No mention | 3–64 m (20 m) | El Escorial criteria | Jianpiyifei decoction | 2 m | None | ALSFRS-R | Stable clinical symptoms | None |
| Luo (2012) [ | TCM syndrome score | Delayed disease progression | None | |||||||||
| Zhao (2013) [ | China | 36 | 23:13 | 53.39 | 3–64 m (18 m) | El Escorial criteria | Jianpiyifei decoction | 2 m | None | MRC muscle scale | Maintenance of quality of life, motor function, and lung function | None |
| Wu (2015) [ | China | 31 | 22:9 | 55.65 | 1–62 m (18.74 m) | El Escorial criteria | Qiangshenjianpi decoction | 3 m | None | ALSFRS-R | Improvement of the TCM symptom score | None |
| Meng (2018) [ | China | 29 | 19:10 | No mention | No mention | Guidelines for the diagnosis and treatment of ALS in China |
| 3 m | Acupuncture | TCM syndrome score | Improvement of the TCM syndrome score, ADL-Barthel index, and ALSFRS-R | None |
| Wen et al. (2019) [ | China | 30 | 18:12 | 55.9 | 3–84 m (20 m) | Guidelines for the diagnosis and treatment of ALS in China | Jianpiyifei decoction | 8 w | Riluzole | ALSFRS-R | Improvement of the TCM symptom score | None |
Details are not specified. M, male; F, female; d, day(s); w, week(s); m, month(s); TER, total effective rate; TCM, traditional Chinese medicine; MRC, Medical Research Council; EMG, electromyography; ALSFRS, amyotrophic lateral sclerosis functional rating scale; ALSFRS-R, ALSFRS-Revised; ALSSS, Amyotrophic lateral sclerosis severity scale; ALSAQ, Amyotrophic lateral sclerosis assessment questionnaire; and ADL, activities of daily living.
Review of randomized controlled trials.
| First author (year) | Country | Sample size (T/C) | Sex (M:F) | Average age (T/C) | The average duration of disease (T/C) (m) | Diagnosed by | Intervention | Duration of treatment | Outcomes | Significant findings | Side effects ( |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Chin et al. (2012) [ | China | 37 (23/14) | (T) 18:5 | 74.5 | No mention | El Escorial criteria | (T) Liqitongbianxieding decoction, general treatment, acupuncture, massage | 14d | TER | TER T 100%, C 83.3% | Diarrhea(2) |
| Jin (2013) [ | China | 28 (15/13) | (T) 11:4 | 54.45 (57.83/50.54) | (18.62/18.25) | ALS diagnosis criteria | (T) Guiluerxianjiaojiajian, riluzole, acupuncture | 6 m | ALSFRS-R | Compared with the control group, the treatment group showed a lower decrease in the ALSFRS-R score | None |
| Pan et al. (2013) [ | China | 42 (23/19) | (T) 14:9 | 50.4 (51.6/50.1) | (25.9/26.1) | El Escorial criteria | (T) Jiaweisijunzitang | 6 m | ALSFRS | Limbs first attacked in patients in the treated group had a smaller rate of change of ALSFRS scores | Constipation(2) |
| Fang (2016) [ | China | 37 (18/19) | (T) 13:5 | 51.31 (49.1/53.4) | (17.6/12.9) | Guidelines for the diagnosis and treatment of ALS in China | (T) Jianpiyifei decoction | 12w | Frenchay | No statistical significant difference | No mention |
| Bao et al. (2016) [ | China | 45 (24/21) | (T) 15:9 | No mention | No mention | El Escorial criteria | (T) Jiaweisijunzitang, general treatment | 6 m | TCM spleen deficiency symptoms score | Delayed TCM deterioration | No mention |
| Zhu et al. (2017) [ | China | 45 (24/21) | (T) 15:9 | No mention | No mention | El Escorial criteria | (T) Jiaweisijunzitang, general treatment | 9 m | ALSFRS-R | Delaying the deterioration of related symptoms and ALSFRS-R | None |
| Gao et al. (2017) [ | China | 42 (22/20) | (T) 14:8 | 50.4 (50.2/50.7) | (23.9/24.3) | El Escorial criteria | (T) Jian Pi Lian Se Tang | 6 w | QS | Improving the scores of the QS, FNU, and ESS | None |
| Yang (2019) [ | Korea | 30 (19/11) | (T-1) 5:5 | 56.47 (54.50/58.30/56.60) | No mention | El Escorial criteria | (T-1) Mecasin | 12 w | ALSFRS-R | K-ALSFRS-R were significantly decreased in the (C) compared to (T-1), (T-2) | (T) |
Curcuma longa, Salvia miltiorrhiza, Gastrodia elata, Chaenomeles sinensis, Polygala tenuifolia, Paeonia lactiflora, Glycyrrhiza uralensis, Atractylodes lancea, and Aconitum carmichaeli. It is a 30% ethanol extraction. T, treatment group; C, control group; M, male; F, female; w, week(s); m, month(s); TER, total effective rate; ALSFRS, amyotrophic lateral sclerosis functional rating scale; ALSFRS-R, ALSFRS-Revised; SF, short from; TCM, traditional Chinese medicine; ALSSS, amyotrophic lateral sclerosis severity scale; ESS, Epworth sleepiness scale; QS, quantity of salivation/sialorrhea; FNU, frequent nighttime urination; MRC, Medical Research Council; VAS, visual analogue scale; HRSD, Hamilton rating scale for depression; FSS, fatigue severity scale; and PGIC, patient global impression of change.
Summary of the revised El Escorial Diagnostic criteria for ALS.
| Diagnosis | Involved segments |
|---|---|
| Clinically possible ALS | UMN and LMN signs in one region; UMN signs in at least two regions; or UMN and LMN signs in two regions without UMN signs rostral to the LMN signs |
| Laboratory-supported probable ALS | UMN signs in one or more regions and LMN signs in at least two regions defined by electromyography |
| Clinically probable ALS | UMN and LMN signs in two regions with some UMN signs rostral to the LMN signs |
| Clinically definite ALS | UMN and LMN signs in three regions |
UMN: upper motor neuron and LMN: lower motor neuron.